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Tacrolimus is an immunosuppressant that exerts its activity via 
suppression of cellular immunity by binding to FKBP-12 to form 
a complex with calcineurin-dependent proteins to inhibit calci-
neurin phosphatase activity and subsequently T lymphocyte acti-
vation. Approved by the Federal Drug Administration (FDA) under 
the brand name Prograf® in 1994, immediate-release tacrolimus 
(IR-TAC) is now considered the backbone of maintenance immuno-
suppressive regimens in solid organ transplantation (SOT). In the 
United States (US), it is reported that more than 70% of SOT re-
cipients are initiated on a TAC-based regimen (SRTR 2018 Annual 
Report). The extensive use of tacrolimus is likely attributable to its 
superiority in prevention of allograft rejection, particularly in the 
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Given the current climate of drug shortages in the United States, this review sum-
marizes available comparative literature on the use of alternative immunosuppressive 
agents in adult solid organ transplant recipients including kidney, pancreas, liver, lung, 
and heart, when immediate-release tacrolimus (IR-TAC) is not available. Alternative 
options explored include extended-release tacrolimus (ER-TAC) formulations, cyclo-
sporine, belatacept, mammalian target of rapamycin inhibitors, and novel uses of in-
duction therapy for maintenance immunosuppression. Of available alternatives, only 
ER-TAC formulations are of non-inferior efficacy compared to IR-TAC when used de 
novo or after conversion in stable kidney transplant recipients (KTRs). All other alter-
natives were associated with higher rates of biopsy-proven rejection, but improved 
tolerance from classic adverse effects of IR-TAC including nephrotoxicity and devel-
opment of diabetes. While most alternative therapies are approved in KTRs, access 
via third-party payors is an obstacle in non-KTRs. In the setting of IR-TAC shortage, 
alternate therapeutic options may be plausible depending on the organ population 
and individual patient situation to ensure appropriate, effective immunosuppression 
for each patient.
K E Y W O R D S
anti-proliferative agent; immunosuppressant, calcineurin inhibitor (CNI); immunosuppressant, 
fusion proteins and monoclonal antibodies; immunosuppressant, immunosuppression/
immune modulation; immunosuppressant, mechanistic target of rapamycin (mTOR)
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setting of renal transplant. This benefit has been demonstrated 
even when comparing to the other agent in its class, cyclosporine 
(CYA).1,2 Given favorable allograft outcomes, IR-TAC alternatives 
are typically reserved for special circumstances, such as to ad-
dress patient tolerability, comorbidities, and very recently, IR-TAC 
availability.
As of spring 2019, a manufacturing shortage of generic IR-TAC 
capsules has limited its access in the United States.3 The prolonged 
national shortage without a definite resolution timeline has cre-
ated an urgent need to identify appropriate candidates for and ap-
plications of IR-TAC alternatives. The aim of this piece is to review 
available literature and concisely summarize the use of each IR-TAC 
alternative and associated outcomes with a focus on providing a 
comparative efficacy summary, clinical pearls, and a risk and bene-
fit evaluation. Alternative IR-TAC options explored include extend-
ed-release formulations of TAC (ER-TAC), cyclosporine, belatacept, 
mammalian target of rapamycin inhibitors (mTORis), and novel ap-
plication of induction therapy for maintenance immunosuppression.
2  | METHODS
A	 systematic	 review	 of	 English	 language	 articles	 using	 PubMed,	
the	Cochrane	Controlled	Trials	Register	(1960-2019),	and	EMBASE	
(1991-2019) for studies evaluating the efficacy, safety, and dosing 
strategies for conversion from a IR-TAC-based immunosuppres-
sive regimen to an alternative agent in adult (age > 18 years) SOT 
recipients was conducted in September 2019. Additional studies 
were identified by searching bibliographies and abstracts presented 
at the American Transplant Congress (1990-2019). There were no 
restrictions on study design. Search terms included tacrolimus, cy(i)
closporine, belatacept, mTOR inhibitor, sirolimus, everolimus, basi-
liximab, daclizumab, interleukin 2 receptor antagonists, thymoglobu-
lin, alemtuzumab, lymphocyte-depleting induction, and calcineurin 
inhibitor (CNI) avoidance. When evaluating comparative efficacy, 
preference was given to studies directly comparing IR-TAC to the 
agent in question. In the setting where these studies were not avail-
able, preference was given to studies comparing similar outcomes. 
Eligibility assessment was performed independently in a standard-
ized and unblinded manner by two reviewers.
2.1 | Calcineurin inhibitor alternatives
2.1.1 | Extended-release tacrolimus formulations
When IR-TAC is unavailable, substitution with an ER-TAC formula-
tion is a desirable and logical conversion (Appendix 1). Two ER-TAC 
formulations are approved by the FDA for prophylaxis of organ re-
jection in KTRs: ER-TAC capsules (XL-TAC; Advagraf® or Astagraf 
XL®; Astellas Pharma) and ER-TAC tablets (LCPT; Envarsus XR®; 
Veloxis Pharmaceuticals). These agents are administered once daily 
by mouth in the morning, ideally on an empty stomach.4,5 Although 
there are data to support the use of 21- or 27-hour levels with LCPT, 
monitoring usually consists of 24-hour TAC trough measurement.4-6
2.1.2 | Extended-release tacrolimus 
pharmacokinetics and pharmacodynamics
Despite extended-release properties, XL-TAC and LCPT have mark-
edly different pharmacokinetic profiles and dosing requirements. 
XL-TAC is slowly released through the addition of ethylcellulose, 
hypromellose, and lactose monohydrate.4 Pharmacokinetic stud-
ies demonstrate similar 24-hour area under the curve (AUC0-24), 
time to maximum concentration (Tmax), and maximum concentra-
tion (Cmax) between IR-TAC and XL-TAC at the recommended 1:1 
conversion, but higher dosages of XL-TAC may be required to main-
tain similar trough concentrations (Cmin) to IR-TAC.7 LCPT, a novel 
formulation	utilizing	MeltDose® technology, has enhanced solubility 
and bioavailability and requires lower dosing requirements com-
pared to both IR-TAC and XL-TAC.5 Studies demonstrated a similar 
AUC0-24 but lower Cmax with LCPT compared to IR-TAC and XL-
TAC.7 The recommended conversion ratio for LCPT is 80% of the 
total daily dose of IR-TAC. Similar to IR-TAC, higher doses of both 
XL-TAC and LCPT may be needed in African American patients.4,5
Due to its unique absorption properties, LCPT partially by-
passes	metabolism	by	CYP3A5	enzymes	in	the	proximal	intestine.8 
This property is beneficial for CYPA5*1 allele expressers, which is 
common in African Americans and may be associated with poor 
outcomes.9,10	 Differences	 in	 the	 extent	 of	 metabolism	 by	 CYP3A	
enzymes also make LCPT less susceptible to certain drug interac-
tions.11 Additionally, a lower Cmax achieved by LCPT decreases 
peak-related side effects, such as neurotoxicities.12 Both the regu-
lated absorption and reduction in peaks have led to speculation that 
use may reduce opportunistic infections, such as BK polyomavirus, 
but this theory requires further investigation.13 Importantly, while 
absorption is regulated, LCPT does not necessarily reduce trough 
intra-patient variability.14
2.1.3 | Extended-release tacrolimus efficacy
XL-TAC has been studied as both conversion from IR-TAC and de 
novo post-transplantation. When investigated in KTR as conversion 
from IR-TAC (1:1), patient and graft survival were excellent (100% 
and	98.5%,	respectively),	with	low	rates	of	biopsy-proven	acute	re-
jection (BPAR) (6%).15 Additionally, when IR-TAC and XL-TAC were 
compared	 to	 CYA	 de	 novo,	 no	 difference	 was	 demonstrated	 in	 a	
composite endpoint of death, graft loss, BPAR, or loss to follow-up 
(14%,	95.2%	CI:	−9.9%-4%	in	the	XL-TAC	group	vs	15.1%,	95.2%	CI:	
−8.9%-5.2%	in	the	IR-TAC	group	vs	17%	in	the	cyclosporine	group).16 
A recent meta-analysis of 11 randomized controlled trials (RCTs) 
comparing IR-TAC to XL-TAC in KTR showed no difference in esti-
mated glomerular filtration rate (eGFR) 12 months post-transplant 
(mean	difference	of	−0.49	mL/min/1.73	m2;	95%	CI:	−2.41-1.42)	and	
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BPAR	at	6	months	(RR	1.03;	95%	CI:	0.82-1.28,)	or	12	months	(RR:	
1.11;	95%	CI:	0.88-1.40).17 Additionally, 12-month graft and patient 
survival	were	not	different	between	groups	(RR:	1.01;	95%	CI:	0.99-
1.03	and	RR:	1.00;	95%	CI:	0.99-1.02,	respectively).	Of	note,	one	of	
the studies included the LCPT formulation.
XL-TAC conversion has also been studied in pancreas and liver 
transplant recipients (PTR, LTR). While studies evaluating XL-TAC in 
PTRs are limited, one study showed a similar eGFR and a low inci-
dence	of	rejection	(2%),	a	median	of	5.5	(+0.9)	months	after	conver-
sion from IR-TAC to XL-TAC.18 Patient-specific factors to consider 
include risk of gastroparesis leading to variable absorption, or the 
need for enteral administration of medications. The use of de novo 
XL-TAC in PTRs has not been evaluated. Studies investigating the 
use of XL-TAC compared to IR-TAC in LTRs demonstrate no differ-
ence in BPAR at 24 weeks (32.6% vs 29.3%, P	=	.354	in	the	overall	
population)	and	at	12	months	(29.5%	vs	26.9%,	P = .490 in the overall 
population). Patient and graft survival at 12 months were also similar 
between	groups	(85.3%	vs	85.6%,	P = .876).19
The use of XL-TAC in thoracic transplant yielded comparable 
results to abdominal transplant. One study in heart transplant re-
cipients, however, demonstrated a significantly lower incidence of 
rejection 2 years after conversion (pre-conversion: 7.6 per 100 pa-
tient-years vs postconversion: 2.1 per 100 patient-years; P < .0001).20 
Study of de novo use in thoracic transplant patients found no differ-
ence in rejection rates.21 Additionally, no differences in survival or 
infection have been seen across studies.20-22 Acknowledging limited 
data, the use of XL-TAC in the heart transplant recipients appears 
safe, with no difference in clinical outcomes. Few studies exist, 
which compare XL-TAC to IR-TAC in lung transplant recipients.23-25 
One study in 12 cystic fibrosis (CF) patients after lung transplanta-
tion found no episodes of rejection up to two years postconversion 
from IR-TAC to XL-TAC, despite a 28%-67% increased dose require-
ment in 82% of the patients.24 Given these data, CF patients may 
require higher doses of XL-TAC compared to IR-TAC, although this 
has been debated.25
Studies investigating LCPT have shown similar outcomes com-
pared to IR-TAC in adult KTR in the de novo and conversion set-
tings.	A	study	of	543	adult	KTRs	randomized	to	de	novo	LCPT	versus	
IR-TAC demonstrated similar efficacy failure rates (LCPT 18.3% vs 
IR-TAC	19.6%;	95%	CI:	−7.94,	5.27%)	at	12	months.26 In addition, de-
layed graft function rates were similar, despite higher early troughs 
in the LCPT group.26	 A	 follow-up	 study	 of	 507	 subjects	 demon-
strated the non-inferiority of LCPT failure rate was maintained at 
24	months	(LCPT	23.1%	versus	IR-TAC	27.3%;	95%	CI:	−4.2,	4.2).27 
A study of 324 adult KTR approximately two years after transplant 
randomized to convert from IR-TAC to LCPT versus remain on IR-
TAC showed similar efficacy failure rates between groups up to 
12	months	 after	 conversion	 (LCPT	 2.5%	 vs	 IR-TAC	 2.5%;	 95%	CI:	
−4.2,	4.2).28 Although no outcome differences were shown in these 
studies, a pooled post hoc analysis of the 12-month de novo and 
conversion results showed that African American patients and pa-
tients	>65	years	old	using	LCPT	had	lower	rates	of	treatment	failure	
compared to IR-TAC.29
Two conversion studies and one de novo study of LTRs suggest 
no differences in safety or efficacy with LCPT as compared to IR-
TAC or XL-TAC.30-32 A case series of eight PTRs found that LCPT 
conversion was well tolerated and led to reduction in adverse drug 
effects (ADEs) that led to conversion. In this small population, less 
aggressive empiric adjustments from IR-TAC to LCPT were needed 
than suggested by the manufacturer.33 Limited data exist for LCPT in 
thoracic transplant recipients. A pharmacokinetic study of 20 stable 
lung transplant recipients converted from XL-TAC to LCPT demon-
strated the conversion to be safe and effective up to six months after 
transplant.34 No published studies in heart transplant recipients 
were identified, although one trial is ongoing.35
Although not extensively studied in LTR and PTRs, the lower 
Cmax of LCPT compared to IR-TAC may be a unique advantage in 
this population. Reduced risk of neurotoxicity is attractive given 
pre-existing neurologic issues due to the primary disease leading to 
transplantation and more complex postoperative courses.
Extended-release tacrolimus is not available as generic prod-
ucts, so out-of-pocket costs and insurance coverage are often vari-
able. Studies performed in Europe have, however, demonstrated 
a cost-benefit for LCPT due to lower dosing requirements.31,36 
Adherence, as assessed by validated questionnaires, may also be im-
proved with once-daily dosing based on two studies of transplant 
recipients converted from IR-TAC to XL-TAC.37,38 As of January 
2020, patient assistance remains available through the drug manu-
facturer of LCPT for qualifying patients in the United States. Overall, 
approval is challenging in the setting of non-KTRs. Insurers often 
require prior authorization as well as written documentation of neu-
rotoxicity. Trough variability has not been an approved indication by 
insurance companies, as this has not been a demonstrated benefit 
of	LCPT.	Although	many	may	require	“failure”	of	CYA	or	an	mTORi	
documentation, this can often be overcome with peer-to-peer com-
munication or appeal.
In summary, ER-TAC has shown non-inferior efficacy compared 
to IR-TAC when used de novo or after conversion in stable KTRs. 
They have not been associated with increased nephrotoxicity and 
are possibly associated with improved adherence. Although not 
FDA-approved in non-KTRs, available data suggest that they are 
also safe and effective in these populations. LCPT may have the ad-
ditional benefits of less erratic pharmacokinetics and lower Cmax 
concentrations, thereby improving neurotoxicity compared to IR-
TAC. Limited payor coverage of extended-release preparations is the 
primary barrier to utilizing these agents.
2.1.4 | Cyclosporine
If an IR-TAC product is unavailable, substitution with an alternative 
CNI	 is	 logical.	 The	 approval	 of	 cyclosporine	 (CYA)	 revolutionized	
transplant medicine with its cell-mediated specificity and marked 
improvement in rejection rates and one-year graft survival.39 
Currently,	 CYA	 is	 FDA-approved	 for	 the	 prophylaxis	 of	 organ	 re-
jection	 in	KTRs,	LTRs,	and	heart	 recipients.	Two	forms	of	CYA	are	
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available as non-modified and modified preparations, which are not 
interchangeable.
Despite	 early	 widespread	 success	 with	 CYA,	 use	 has	 been	
largely replaced by IR-TAC due to greater immunosuppressive po-
tency, reduced intra-patient pharmacokinetic variability, improved 
rates of rejection, and possibly superior allograft survival.40	Many	
studies	and	meta-analyses	comparing	 IR-TAC	to	CYA	across	organ	
types have demonstrated such findings; however, existing studies 
have also shown conflicting results.41 A meta-analysis performed by 
Webster and colleagues demonstrated that using IR-TAC rather than 
CYA	in	100	KTRs	prevents	acute	rejection	in	12	patients	(RR:	0.69,	
95%	CI:	0.60	to	0.79)	and	graft	loss	in	two	patients	(RR:	0.56,	0.36	
to 0.86) in the first post-transplant year.1 IR-TAC benefits are main-
tained even when targeting lower trough concentrations to minimize 
nephrotoxicity, as demonstrated in the ELITE-Symphony trial. This 
study found low-dose IR-TAC when compared to both low-dose 
and	standard-dose	CYA	to	be	associated	with	lower	rates	of	rejec-
tion	(12.3%,	24%,	and	25.8%,	P < .001) and superior renal function, 
GFR	 (mL/min)	 (65.4,	59.4,	57.1,	P < .001) 1 year post-transplant.42 
In LTRs, a meta-analysis of RCTs published since 2000 showed IR-
TAC	was	superior	to	CYA	in	terms	of	patient	mortality	(RR	with	CYA	
1.26,	 1.01-1.58)	 and	 hypertension	 (RR	 with	 CYA	 1.26,	 1.07-1.47),	
while	CYA	was	superior	in	terms	of	new-onset	diabetes	after	trans-
plant (NODAT). No significant differences were identified in graft 
loss or acute rejection.2	 IR-TAC	was	also	more	effective	 than	CYA	
in preventing moderate or severe kidney or pancreas rejection (3% 
vs 28%, P = .009) after pancreas-kidney transplantation in a 3-year 
study.43 It also provided superior pancreas survival (89.2% vs 72.4%; 
P = .002) and reduced the risk of pancreas graft thrombosis. Similar 
findings have been demonstrated in cardiothoracic transplant in 
meta-analyses of RCTs with comparable 1-year survival between 
agents (heart P = .11, lung P = .88), but increased rates of NODAT 
(heart P = .003, lung P = .03) and reduced incidence of 1-year graft 
rejection attributed to TAC (heart P = .04, lung P = .04).44,45
Although CNIs have significantly improved transplant outcomes, 
ADEs associated with these agents can ultimately compromise long-
term patient and graft outcomes. IR-TAC shares many ADEs with 
CYA,	including	nephrotoxicity,	neurotoxicity,	and	infectious	compli-
cations. Beyond these toxicities, the CNIs have differing ADE pro-
files	that	help	guide	practitioners	in	selection	between	agents.	CYA	
increases cardiovascular risk with a greater incidence of hyperten-
sion and hyperlipidemia, whereas IR-TAC is associated with a greater 
risk of NODAT.2
In	mycophenolate	mofetil	(MMF)–treated	organ	transplant	recip-
ients,	 lower	mycophenolic	 acid	 (MPA)	plasma	concentrations	have	
been	found	with	CYA	compared	to	TAC-based	regimens.	This	is	the	
result	 of	 CYA-mediated	 inhibition	 of	 MPA	 glucuronide	 conjugate	




dose IR-TAC or low-dose sirolimus (SRL) had greater concentrations 
of	MPA	and	its	active	metabolite	at	various	time	points	(P	<	.05).47
There	 is	 some	 evidence	 for	 the	 use	 of	 CYA	 in	 certain	 special	
populations. In KTR renal failure secondary to focal segmental glo-
merulosclerosis	(FSGS),	evidence	suggests	CYA	may	decrease	FSGS	
recurrence post-transplant.48 In patients who develop posterior 
reversible encephalopathy syndrome (PRES) while taking IR-TAC, 
switching	to	CYA	may	be	a	reasonable	alternative	given	alternative	
mechanisms of action for causing PRES.49
In	 summary,	 IR-TAC	 has	 replaced	 CYA	 as	 the	 preferred	 CNI	
post-transplant. However, in the setting of a drug shortage or un-
availability,	CYA	may	be	used	to	prevent	rejection	following	trans-
plant. Practitioners should consider the differing ADE profile and 
counsel	 patients	 appropriately.	 Additionally,	 MMF	 dosing	 adjust-
ments	 may	 be	 necessary	 when	 switching	 from	 IR-TAC	 to	 CYA	 to	
account	 for	 lower	 MPA	 AUC.	 Finally,	 special	 patient	 populations	
may	benefit	from	utilization	of	CYA	over	alternative	IR-TAC	replace-
ments, such as those experiencing neurotoxicity or NODAT and pa-
tients with a primary diagnosis of FSGS.
2.2 | Non-Calcineurin inhibitor alternatives
When alternative CNIs are either not appropriate or not available for 
use in a particular patient, the clinician must turn to a non-CNI-based 
regimen. Overall, these regimens are plagued by higher incidence of 
BPAR than IR-TAC-based regimens; however, careful patient selec-
tion can improve successful outcomes. The following section sum-
marizes	 the	 use	of	MTOR-Is,	 belatacept,	 and	 induction	 agents	 for	
CNI dose sparing or avoidance.
2.2.1 | MTOR-Is (Sirolimus, Everolimus)
Currently, two orally administered mammalian target of rapamy-
cin inhibitors (mTORis), sirolimus (SRL) and everolimus (EVR), are 
available for the prophylaxis of organ rejection in adult transplant 
recipients. SRL was the first available, FDA-approved in 1999, with 
EVR following approximately ten years later in 2010.50 Both agents 
inhibit protein synthesis and cell cycle progression via binding to 
rapamycin and the FK binding protein 12 (FKBP-12) and ultimately 
inhibiting IL-2-induced T-, NK, and B-cell proliferation.51 Although 
site of actions is similar, EVR has a shorter half-life, improved bio-
availability, and lower average target blood trough concentrations 
(3-10	ng/mL	vs	4-15	ng/mL)	compared	to	SRL.50,52
The mTORis differ from IR-TAC via their mechanisms of action, 
adverse event profiles, and the potential to have anti-proliferative 
effects, anti-angiogenic effects, anti-viral effects, and reduced 
nephrotoxicity. Commonly, mTORis are used in combination with 
other immunosuppressant agents either to increase cumulative drug 
exposure or to minimize toxicities.
Complete avoidance or withdrawal of CNI with mTORi substitu-
tion in KTRs has been extensively evaluated, including meta-analysis 
of multiple RCTs.53 In large, these studies demonstrate an increase 
in	acute	rejection	with	a	reduction	in	malignancy	and	CMV,	as	well	
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as some improvement in renal function. Death and graft loss are typ-
ically not different between groups, and neither type of CNI nor a 
steroid-free regimen appeared to influence outcomes. The de novo 
use of lower dose SRL (trough range 4-8 ng/mL) in the setting of 
daclizumab	induction	in	combination	with	MMF	and	prednisone	has	
resulted in increased BPAR (37.2% vs 12.3% in IR-TAC arm; P < .001) 
and reduced allograft survival (89.3% vs 94.2% in IR-TAC arm) at 
12 months.42	 The	 de	 novo	 use	 of	 SRL/MMF	 with	 higher	 trough	
ranges	 of	 10-15	 ng/mL	 in	 the	 immediate	 post-transplant	 period,	
however, has not resulted in increased BPAR or reduced allograft 
survival	 and	 is	 favorably	 associated	 with	 a	 15-17	 mL/min	 higher	
eGFR	compared	to	non-SRL/MMF	comparator	arms.54,55
Studies investigating conversion from CNI to mTORi in KTRs also 
demonstrate improvement in GFR; however, this benefit is often 
lost with late conversion.56 Conversion within 6 months post-trans-






The CONVERT trial stratified 830 KTRs according to baseline 
GFR	(20-40	mL/min	or	>	40	mL/min)	and	randomized	to	SRL/MMF	
or	remain	on	CNI/MMF	at	6-120	months	post-transplant.56 Patients 
with a baseline GFR >40 mL/min had a higher mean GFR after SRL 
conversion	at	all	 time	points	 (24-month	GFR	62.6	vs	59.9	mL/min;	
P = .009). Graft and patient survival and BPAR were similar between 
groups. Enrollment in the GFR 20-40 mL/min stratum was halted 
prematurely due to a higher incidence of the safety endpoint of the 
composite rate of the first occurrence of BPAR, graft loss, or death 
12 months after randomization among the SRL-converted patients. 
Additionally, post hoc analyses revealed that the risk-benefit profile 
was most favorable in the baseline GFR >40 mL/min subgroup and 
those	with	a	protein:creatinine	ratio	(UPr/Cr)	≤0.11.
The	TRANSFORM	trial	evaluated	2037	de	novo	renal	transplant	
recipients in a prospective, open-label design. Patients were ran-
domized 1:1 within 24 hours post-transplant to receive EVR (trough 
range	3-8	ng/mL)	with	 reduced-exposure	CNI	or	MMF	with	 stan-
dard-exposure CNI.63 The 24-month data were recently published 
and were consistent with the 12-month data demonstrating com-
parable efficacy between groups.64 The EVR and reduced-exposure 
CNI were non-inferior to standard-exposure CNI for the primary 
endpoint	of	treated	BPAR	or	eGFR	<50	mL/min/1.73	m2. While the 
incidence of de novo donor-specific antibodies (12.3% vs 17.6%), 
CMV	(2.8%	vs	13.5%),	and	BK	virus	infections	(5.8%	vs	10.3%)	was	
lower in the EVR and reduced-exposure CNI arm, discontinuation 
rates	due	to	adverse	events	were	higher	(27.2%	vs	15%).	This	is	the	
largest study to date that demonstrates the advantages of EVR with 
reduced-exposure CNI in de novo renal transplant recipients.
Conversion to mTORi with CNI withdrawal in LTRs has been 
investigated for kidney dysfunction, intolerance to CNI, to delay 
hepatocellular carcinoma recurrence, and in the management of 
post-transplant malignancies.65-69 Efficacy is highly dependent on 
the time after liver transplant, concomitant immunosuppression, 
and use of induction therapy. Similar to KTR, data demonstrate an 
increased risk of rejection, but often an improvement in renal func-
tion,	 especially	 if	 conversion	 occurs	 early	 (≤6	 months	 post-trans-
plant). Several studies investigated early use of mTORi with CNI 
withdrawal,66-69 and many demonstrated an increased risk of BPAR. 
This was confirmed in a meta-analysis including four RCTs, which 
associated early mTORi use with a 71% increase in risk of BPAR (RR: 
1.71;	95%CI:	1.15-2.53;	P < .01).70 Despite this increase in rejection, 
eGFR improvements 12 months post-transplant range from 8 to 
27 mL/min/1.73 m2 across studies.66,68,69
Data evaluating mTORi use with CNI avoidance or withdrawal 
post–heart	transplant	have	shown	similar	outcomes	to	other	organ	
groups: an increased risk of BPAR, improved renal function, reduced 
incidence	of	CMV,	high	discontinuation	rates,	and	no	difference	 in	
patient	 and	 allograft	 survival	 when	 compared	 to	 CNI/MMF	 regi-
mens.71-73	The	additional	benefit	of	mTORi	use	post–cardiac	trans-
plant is its impact on coronary allograft vasculopathy (CAV). The 
SCHEDULE trial randomized de novo heart transplant recipients 
who received rabbit anti-thymocyte globulin (ATG) induction to 
EVR (trough 6-10 ng/mL) with reduced CNI followed by CNI with-
drawal at weeks 7-11 or to a conventional CNI-based regimen.74 At 
the end of the 12-month trial, the EVR-treated patients had signifi-
cantly better renal function and significantly lower incidence of CAV, 
but	higher	BPAR	 rates	 compared	 to	 the	CNI	 cohort	 (73%	vs	52%;	
P	<	.05).	The	36-month	data	showed	a	GFR	difference	of	18.3	mL/
min between groups and continued improvement in CAV; however, 
increased BPAR and high discontinuation rates were notable in the 
EVR cohort.73	 The	benefits	of	 renal	 function	and	CAV	post–heart	
transplant should be weighed with the risk of BPAR.
Data to support the efficacy of CNI withdrawal and mTORi con-
version after lung transplantation are limited to single-center trials 
without CNI comparison.75,76 No detrimental effect on pulmonary 
function or outcomes has clearly been documented in the conver-
sion setting, but comparative efficacy has not been evaluated. De 
novo use is not preferred given effects on anastomotic healing.77 
Given the high incidence of acute and chronic rejection after lung 
transplantation, complete CNI withdrawal is generally not recom-
mended. The same is true for CNI withdrawal with mTORi conver-
sion after pancreas transplant.78
Recommendations regarding conversion from a CNI to an mTORi 
post-transplant vary by allograft type. The conversion from a CNI to 
an	mTORi	post–kidney	transplant	can	be	considered	in	the	setting	of	
adequate allograft function (GFR > 40 mL/min) and absence of pro-
teinuria	(UPr/Cr	≤	0.11).	Post–liver	transplant,	mTORi	conversion	can	
be associated with rejection, so adjunctive antimetabolite is advised. 
In addition, the transition to mTORi should be gradual and over an 
extended period of time when possible. High rejection rates follow-
ing	CNI	to	mTORi	conversion	post–heart	transplant	make	conversion	
riskier; however, when no alternative exists, it can be done while op-
timizing	trough	levels	in	conjunction	with	MMF	and	corticosteroids.	
Finally, in lung and PTRs, mTORi therapy with complete CNI with-
drawal is generally not recommended due to higher rejection risks. 
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Additionally,	 if	used	post–lung	transplant,	endoscopic	confirmation	
of anastomotic healing is necessary prior to conversion given the 
risk of poor airway healing and anastomotic dehiscence.77 Outside 
of KTRs, in which mTORis have been used de novo or for early con-
version, initiation of mTORi is typically not recommended until after 
30 days post-transplant due to impaired wound healing and anasto-
motic dehiscence.
Therapeutic drug monitoring of mTORis is recommended for all 
patients to ensure efficacy and safety. Therapeutic optimization may 
be delayed when drug-level analysis occurs via send-out laboratories 
as obtaining results may be postponed. Additionally, given the long 
t1/2 of mTORis vs CNIs, therapeutic drug monitoring and dose titra-
tion should be done at a slower rate than typically used for IR-TAC.
Common ADEs include hyperlipidemia, edema, leukopenia, 
anemia, stomatitis, proteinuria, and wound healing complications 
(including wound dehiscence, incisional hernia, lymphocele). ADEs 
can generally be managed with close monitoring and follow-up, and 
many are manageable with adjuvant treatment or reversible upon 
discontinuation	of	mTORi.	More	significant	and	severe	ADEs	include	
an increased risk of thromboembolism and interstitial pneumonitis. 
An important consideration of mTORi is that the ADE-related drop-
out rate in clinical trials is 20%-40%.79 Additionally, no generic for-
mulation is currently available for EVR, so this agent may be cost 
prohibitive for certain patients.
In summary, the use of mTORi-based regimens devoid of CNIs 
has demonstrated efficacy. However, careful consideration is re-
quired related to patient population, time post-transplant, concomi-
tant immunosuppression, potential for rejection, and ADE profile to 
ensure safety. For all organ types, mTORis should be used in con-
junction	with	adjunctive	therapies	(ie	MMF	and	corticosteroids)	to	
minimize risk of rejection. Trough mTORi levels should be optimized, 
and the transition to mTORi should be gradual and over an extended 
period of time when possible. Utilization as part of a CNI dose-spar-
ing regimen could also be pursued. The frequency of post-transplant 
follow-up and clinical assessments should be amplified, and per-
sistent vigilance to diagnose and manage therapy-related toxicities 
is required to ensure optimal outcomes.
2.2.2 | Belatacept
In 2011, a novel immunosuppressive agent, belatacept, administered 
via monthly intravenous infusion, was FDA-approved for use in 
KTRs. Belatacept exerts its effect via binding to CD80 and CD86 li-
gands on antigen-presenting cells, thereby blocking CD28-mediated 
co-stimulation of T lymphocytes.80 Belatacept was approved follow-
ing two randomized, multicenter non-inferiority trials that compared 
belatacept-based	regimens	to	CYA.81,82 The dosing and administra-
tion schedule of belatacept varies, depending on indication. De novo 
dosing	is	10	mg/kg	IV	postoperative	day	1,	day	5,	week	2,	week	4,	
week	8,	and	week	12,	followed	by	a	maintenance	dose	of	5	mg/kg	
every 4 weeks.80 Currently, an FDA-approved dosing scheme for 
late	conversion	does	not	exist	but	studies	suggest	5	mg/kg	on	days	
1,	 15,	 29,	 43,	 and	 57	 followed	 by	maintenance	 of	 5	mg/kg	 every	
4 weeks.83,84
Unlike IR-TAC, belatacept has a standard, weight-based dos-
ing that does not require therapeutic drug monitoring. Belatacept 
is devoid of many of the common side effects of IR-TAC, including 
hypertension, hyperlipidemia, neurotoxicity, and nephrotoxicity.80 
Evidence supports improved GFR with regimens containing belata-
cept as compared to IR-TAC.85-87 Given monthly maintenance dos-
ing, adherence has been proposed as an added benefit of belatacept. 
Despite these benefits, belatacept can cause an early increase in 
proteinuria, the clinical significance of which is unknown and is as-
sociated with an increased risk of rejection.81,85-88 Additionally, be-
latacept was associated with a significant increase in post-transplant 
lymphoproliferative disease (PTLD) in the drug trials, and therefore, 
administration is contraindicated in patients who are EBV IgG-
negative, due to a theoretical increased risk of PTLD in the setting of 
primary EBV infection.80
Studies directly comparing outcomes between de novo IR-TAC 
and belatacept immediately following transplantation have been 
limited to KTRs.85-87 A small, prospective, RCT of adult KTR who re-
ceived basiliximab induction found a higher incidence of rejection in 
the	belatacept	compared	to	the	IR-TAC	arm	(55%	vs	10%;	P = .006).85 
Similar results were seen in a propensity-matched cohort of adult 
KTR discharged on belatacept-based versus TAC-based regimens.86 
Incidence of acute rejection was higher in the belatacept compared 
to	the	IR-TAC	group	(odds	ratio,	3.12;	95%	CI,	2.13-4.57);	there	was	
no difference in mortality or graft loss risk. One-year post-trans-
plant eGFR was significantly lower among IR-TAC compared to bela-
tacept-treated	patients	(median	eGFR	58.5	mL/min/1.73m	vs	eGFR	
62.3 mL/min/1.73m2).86 Consistent with the above studies, Wen 
and colleagues found belatacept was associated with a higher risk 
of 1-year acute rejection compared to IR-TAC, with highest rates as-
sociated	with	non-lymphocyte-depleting	induction	(aHR	2.65,	95%	
CI 1.90-3.70). eGFR was higher with belatacept plus IR-TAC and 
belatacept	alone	versus	 IR-TAC	alone	 (mean	eGFR	65.6,	60.4,	 and	
54.3	mL/min/1.73	m2).87 Lastly, Ferguson and colleagues compared 
outcomes of three cohorts following ATG induction and early ste-
roid	withdrawal:	 belatacept-MMF,	 belatacept-SRL,	 or	 TAC-MMF.88 
The belatacept arm had more BPAR than the other arms (4:1:1), but 
was associated with a higher eGFR (by 8-10 mL/min) than the IR-TAC 
group; overall safety was comparable between groups.
In patients with ongoing delayed graft function (DGF), intoler-
ance to IR-TAC or evidence of IR-TAC toxicity, conversion to be-
latacept may be considered. Conversion of KTRs from IR-TAC to 
belatacept has been studied in both the early (<6 months) and the late 
(>6 months) post-transplant periods. Nair and colleagues found that 
early conversion of patients with delayed or poor graft function from 
IR-TAC to belatacept was both safe and efficacious.83 Additionally, 
studies have suggested that it can improve kidney function, partic-
ularly for patients experiencing prolonged DGF.89 Late conversion 
of KTRs from IR-TAC to belatacept has also been shown to improve 
renal function at the time of conversion, although this improvement 
is not always maintained long term.90
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Off-label use in lung, pancreas, and heart transplant recipients 
has been documented but is limited to individual case reports where 
regimen varied widely.91-93	Most	 individuals	 in	 these	 studies	were	
converted to belatacept due to non-adherence or CNI toxicity. 
Although data are minimal, there may be situations in which belata-
cept may be considered. Additional studies are needed to fully eluci-
date the role of belatacept in these populations.
Belatacept in LTRs is not routinely recommended due to an in-
creased risk of graft loss and death.80,94 However, some centers 
continue to explore its use to avoid ADEs of CNIs and improve ad-
herence.	 A	 study	 by	 LaMattina	 and	 colleagues	 provides	 evidence	
that belatacept use may be beneficial in select patients.95 At this 
time, it is recommended to avoid use after liver transplant, although 
it may be considered as a last line option.
Belatacept use is further complicated due to the manufacturer's 
limited distribution. Clinicians must enroll patients in the Nulojix 
Distribution Program http://www.nuloj ixhcp.bmscu stome rconn ect.
com/servl	et/servl	et.FileD	ownlo	ad?file=00Pi0	00000	nzpG5EAI)	 to	
obtain approval for use and a patient identification number (PIN) 
prior to administration. It is difficult to compare the cost of belata-
cept and IR-TAC due to multiple variables. Insurance approval should 
be obtained prior to initiating therapy and may be challenging in 
non-KTRs given lack of data.
In summary, while belatacept is considered a non-inferior alter-
native to IR-TAC in KTRs, belatacept-treated patients are more likely 
to experience acute rejection. However, despite increased early re-
jection, patients experience a higher eGFR at 1 year than their TAC-
treated counterparts. Belatacept has been explored in non-KTRs, 
but data are limited and the inability to obtain insurance approval 
may significantly limit access. Belatacept is not recommended for 
routine use in LTRs given poor outcomes in initial manufacturer 
studies, although it may be considered in rare cases.
2.3 | Induction agents for maintenance
In SOT, maintenance immunosuppression involves the use of multiple 
agents in combination to prevent allograft rejection. Alternatively, 
induction immunosuppressants such as lymphocyte-depleting 
agents [ATG and alemtuzumab] and interleukin 2 receptor antago-
nists (IL2RAs) [daclizumab and basiliximab] are classically given at 
the time of transplant surgery to prevent acute rejection during this 
highly inflammatory period of initial immune activation. Literature 
exists that describes induction immunosuppressants as part of the 
maintenance regimen and in rare circumstances may be necessary.
2.3.1 | Non-lymphocyte-depleting agents 
(daclizumab, basiliximab)
The	 IL2RAs	are	non-depleting	 induction	agents	 that	block	CD-25,	
the T-cell IL-2 receptor, to prevent proliferation of T cells.96 IL2RAs 
include daclizumab, a humanized monoclonal antibody (discontinued 
in 2009), and basiliximab, a chimerized monoclonal antibody. Drug 
effects last approximately 1-2 months.97 In LTRs, IL2RA induction al-
lows delays in CNI initiation, minimizing CNI exposure and reducing 
nephrotoxicity risk.98-100 While literature is limited to case reports 
and small case series, this technique has been extrapolated to heart, 
pancreas, and KTRs for patients intolerant to CNIs.101-104 Regimens 
range from weekly to monthly IL2RA therapy. One of the first re-
ports of IL2RA maintenance immunosuppression described a mixed 
allograft population of 11 heart, liver, and combined heart-kidney 
transplant recipients initiated on an IL2RA for a “CNI-holiday.” 
Basiliximab	20	mg	every	20	days	or	daclizumab	1.5	mg/kg	weekly	
was given until CNI re-initiation. In this series, patients were main-
tained	on	IL2RAs	for	a	mean	of	52	days	(range	6-210	days).	Patients	
otherwise	received	combinations	of	mTORi,	MMF,	and	corticoster-
oids for maintenance. This study demonstrated that IL2RAs can be 
given to allow resolution of acute renal injury without incidence of 
rejection or adverse effect.101 An additional publication described 2 
cases of de novo IL2RA therapy after KTR, both patients achieving 
successful patient and graft outcomes with a triple-drug regimen of 
MMF,	 steroids,	 and	monthly	basiliximab	at	doses	of	20-40	mg	 for	
over 3 years post-transplant.104 This technique has also been studied 




pared to a matched control.103 While the maintenance regimens in 
the controls were not specified, both groups were steroid-sparing.
Unfortunately, studies demonstrate unacceptably high rates of 
rejection when studied on a larger scale without continuation of 
CNIs. In a study of approximately 100 de novo KTRs, CNI therapy 
was replaced with daclizumab 1 mg/kg every 2 weeks for a total of 
five	doses.	At	1	year,	early	rejection	rates	were	45%	requiring	CNI	
reintroduction in >90% of cases.102 Therefore, ongoing therapy must 
be ensured.
IL2RAs represent an attractive option for CNI replacement due 
to non-depleting mechanism of action, long drug half-life, and limited 
ADEs.	Many	studies	have	evaluated	the	use	of	daclizumab,	which	is	
no longer available, and has different pharmacokinetics than basilix-
imab. Additionally, no head-to-head comparisons with belatacept 
exist, which largely fills this role at a similar cost, and substantiated 
by robust clinical data.
2.3.2 | Lymphocyte-depleting agents (rabbit anti-
thymocyte globulin (rATG), alemtuzumab)
Lymphocyte-depleting agents induce cell lysis, thereby reducing 
circulating lymphoid cell lines.105 Immune reconstitution can take a 
year, although effects may be more prolonged.105 Due to the pro-
found release of cytokines from cellular destruction and the pro-
tracted depletion of cellular lines, ATG and alemtuzumab are less 
tolerable and carry a higher risk for ADEs including infection and 
malignancy compared to the typical maintenance agents.
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To our knowledge, no study describes the use of a ATG, a poly-
clonal antihuman thymocyte immunoglobulin, derived from rabbits 
and resulting in reduction of multiple lymphoid cell lines, but pre-
dominantly	CD3+	T	cells,	in	a	maintenance	regimen.106 Theoretically, 
given its animal derivation, subsequent courses of rATG could be less 
efficacious due to immune sensitization to animal protein content. 
However, while antibodies to rATG have been detected in vitro, the 
creation of anti-rATG antibodies has not had a clinically significant 
impact on rejection treatment.107,108 However, this concern in addi-
tion to safety concerns with continued ongoing dosing likely explains 
the lack of the use of a polyclonal product in maintenance regimens.
Alemtuzumab is a humanized monoclonal antibody targeting 
the	CD52	antigen	widely	expressed	on	lymphocytes,	macrophages,	
monocytes, and eosinophils, which results in prolonged and pro-
found	 depletion	 of	 T-	 and	B-cell	 lines	with	 CD4+	 suppression	 for	
years after administration.109 A single study describes the use of 
alemtuzumab in a maintenance regimen.110 In this prospective 
observational	 cohort	 study	 of	 75	 PTRs	 (43%	 PTA,	 23%	 PAK,	 and	
27% SPK), there were no differences in patient and graft survival 
rates at 6 months when patients received a regimen consisting of 
120 mg alemtuzumab (30 mg POD 0, 2, 14 and 42) and a single dose 
of	 1.25	mg/kg	 rATG	 on	 POD4	 in	 combination	with	MMF	 ≥2	 g/d.	
Additional doses of alemtuzumab were given if absolute lymphocyte 
counts	were	≥200/mm3. Patients could receive a max of 10 doses of 
alemtuzumab in the first year. This regimen was compared to 266 
standard of care patients that received rATG induction and IR-TAC 
maintenance.	If	MMF	was	dosed	<2	g/d	due	to	intolerance,	the	reg-
imen	could	be	modified	by	switching	MMF	to	SRL	or	adding	dacli-
zumab 1 mg/kg every other month (IL2RA maintenance). Steroid use 
and	MMF	dose	in	the	control	group	were	not	specified.	There	were	
no differences in patient and graft survival rates in the 6-month 
follow-up; however, incidence of rejection was significantly higher 
in the study group. Risk of intraabdominal infection, cytomegalovi-
rus infection, and PTLD were not different between groups; how-
ever, patients in the study group were maintained on 12 months of 
valganciclovir.
In summary, the use of depleting induction as part of the main-
tenance regimen is atypical and increases the risk for immediate 
intolerance and long-term infectious and malignant complications. 
Overall, monoclonal antibodies have been studied in this manner, 
primarily IL2RAs, but data are limited. Overall, data suggest an in-
creased risk of rejection compared to CNIs, particularly in the set-
ting of CNI discontinuation. If the use of an induction agent in the 
maintenance regimen is desired due to lack of other viable options, 
careful patient selection is required along with intensified infectious 
prophylaxis to ensure positive patient and allograft outcomes.
3  | CONCLUSION
Our review of available literature investigating the efficacy and 
safety of IR-TAC alternatives demonstrates that all non-TAC-
based regimens are plagued with an increased risk of BPAR, but 
overall improved tolerance particularly related to nephrotoxicity. 
No difference in BPAR exists between ER-TAC formulations and 
IR-TAC, the majority of data with KTRs and LTRs. LCPT may be 
preferred in patients with TAC-associated, or a higher propensity 
for, neurotoxicity due to the achievement of lower peak con-
centrations. Overall, mTORis are associated with higher rates of 
BPAR and discontinuation due to ADEs in kidney, liver, and heart 
transplant recipients, but appear to be associated with reduction 
in opportunistic viral infection and malignancy. Careful patient se-
lection and monitoring are recommended when converting IR-TAC 
to mTORi. Belatacept is an attractive alternative for KTRs expe-
riencing nephrotoxicity or non-adherence and has demonstrated 
positive long-term outcomes. However, no robust data supporting 
the use of belatacept in non-KTR populations exist, making it dif-
ficult to obtain insurance coverage. Belatacept is also associated 
with higher rates of rejection. While data exist describing the use 
of classical induction agents for maintenance, data are limited to 
small case series and special populations. IL2RAs are preferred 
over depleting agents overall; however, belatacept largely fills this 
role with better data, particularly in KTRs. This review confirms 
that tacrolimus is the gold standard with superior outcomes and 
demonstrates that in times of limited IR-TAC availability trans-
plant clinicians should carefully evaluate unique patient modifi-
ers to ensure the best alternative immunosuppressant regimen is 
selected.
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APPENDIX 1
1   Currently available immediate-release (IR) tacrolimus (TAC) alternatives
Options Available Productsa  Benefits compared to IR Tacrolimus Drawbacks compared to IR Tacrolimus
Studies Reviewed with pertinent efficacy and safety findings per organ type. Study type categorized as (A) Randomized Controlled Trial or  
(B) Non-Randomized Controlled Trial









• Reduced serum concentration fluctuations 
(note: not associated with improved TAC trough 
variability)
• Once-daily drug administration
• Potential for improved medication adherence
 
• FDA approval only in KTRs
• Possible payor coverage issues

































• Possible reduced neurotoxicity
• Possible reduction in new-onset diabetes after 
transplant (NODAT)
 
• Increased PK variability
•	 May	lower	mycophenolic	acid	(MPA)	
plasma concentrations
• PK differences between products


















• Reduced risk of coronary allograft vasculopathy 
(CAV)
•	 Reduced	risk	of	viral	infection	(CMV,	BK)
• Once-daily administration with sirolimus
 
• Potential for impaired wound healing 
and anastomotic dehiscence (avoid use in 
first 30 d postop)
• High rates of intolerance (discontinuation 
rates: 17%-26%) proteinuria, 
hyperlipidemia
• PK differences between products








































• Requires IV administration
• Contraindicated in EBV-negative 
recipients
• Avoid use in liver transplant
•	 Manufacturer's	limited	distribution
• Possible payor coverage issues
























• Requires IV administration
• Limited supporting data
• Possible payor coverage issues



















• Possible reduction of CNI-related ADEs
 
• Requires intravenous administration
• No literature supporting rATG
• Single study supporting alemtuzumab
• Increased infectious and malignant risk
• Use requires careful patient selection
(B)	Gruessner	2005
Note: This table summarizes literature referenced in this manuscript and is not inclusive of all published studies supporting drug utilization in these  
allograft subtypes
a For additional details, refer to the individual products prescribing guidelines.  
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1   Currently available immediate-release (IR) tacrolimus (TAC) alternatives
Options Available Productsa  Benefits compared to IR Tacrolimus Drawbacks compared to IR Tacrolimus
Studies Reviewed with pertinent efficacy and safety findings per organ type. Study type categorized as (A) Randomized Controlled Trial or  
(B) Non-Randomized Controlled Trial
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• Single study supporting alemtuzumab
• Increased infectious and malignant risk
• Use requires careful patient selection
(B)	Gruessner	2005
Note: This table summarizes literature referenced in this manuscript and is not inclusive of all published studies supporting drug utilization in these  
allograft subtypes
a For additional details, refer to the individual products prescribing guidelines.  
